DC4U exploits its GlycoDCTM dendritic cell targeting technologies for applications in vaccines, oncology, allergy and auto-immune diseases. Our glycan based technology is applicable to both the development of novel glycan-antigen based therapeutics as well as for modifying existing products. Our business strategy is to offer early stage business and partnering options to the food- and pharmaceutical industry, including licensing and co-development.
You are most welcome to contact us to discuss business and partnering opportunities.
Contact:
DC4U BV
Henk Viëtor
Hollandse Kade 32
1391 JM Abcoude
+31 (0)346 74 5139
henk.vietor@dc4u-technologies.nl